BlackRock’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-499,510
| Closed | -$649K | – | 5454 |
|
|
2025
Q2 | $649K | Sell |
499,510
-1,112,492
| -69% | -$1.34M | ﹤0.01% | 4385 |
|
|
2025
Q1 | $2.24M | Sell |
1,612,002
-25,328
| -2% | -$55.5K | ﹤0.01% | 3960 |
|
|
2024
Q4 | $3.75M | Buy |
1,637,330
+57,166
| +4% | +$151K | ﹤0.01% | 3840 |
|
|
2024
Q3 | $4.3M | Buy |
1,580,164
+78,277
| +5% | +$191K | ﹤0.01% | 3757 |
|
|
2024
Q2 | $3.51M | Buy |
1,501,887
+154,348
| +11% | +$492K | ﹤0.01% | 3809 |
|
|
2024
Q1 | $6.32M | Sell |
1,347,539
-24,693
| -2% | -$128K | ﹤0.01% | 3576 |
|
|
2023
Q4 | $6.7M | Sell |
1,372,232
-72,770
| -5% | -$302K | ﹤0.01% | 3576 |
|
|
2023
Q3 | $6.72M | Buy |
1,445,002
+255,152
| +21% | +$1.47M | ﹤0.01% | 3537 |
|
|
2023
Q2 | $8.79M | Buy |
1,189,850
+193,305
| +19% | +$1.29M | ﹤0.01% | 3475 |
|
|
2023
Q1 | $8.15M | Sell |
996,545
-21,238
| -2% | -$222K | ﹤0.01% | 3426 |
|
|
2022
Q4 | $9.74M | Buy |
1,017,783
+43,004
| +4% | +$529K | ﹤0.01% | 3407 |
|
|
2022
Q3 | $11.5M | Buy |
974,779
+177,176
| +22% | +$2.33M | ﹤0.01% | 3356 |
|
|
2022
Q2 | $10.2M | Buy |
797,603
+20,602
| +3% | +$214K | ﹤0.01% | 3495 |
|
|
2022
Q1 | $8.54M | Buy |
777,001
+10,737
| +1% | +$125K | ﹤0.01% | 3660 |
|
|
2021
Q4 | $11.7M | Buy |
766,264
+355,867
| +87% | +$4.66M | ﹤0.01% | 3580 |
|
|
2021
Q3 | $5.73M | Sell |
410,397
-31,388
| -7% | -$525K | ﹤0.01% | 3905 |
|
|
2021
Q2 | $8.54M | Buy |
+441,785
| New | +$9.12M | ﹤0.01% | 3698 |
|
BlackRock's AKYA Position: Q3 2025 in Review
BlackRock sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 499,510 shares — an estimated $649K sold.
BlackRock first reported a position in AKYA in Q2 2021 and held it in 17 quarters. The position peaked at $11.7M in Q4 2021. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- BlackRock reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 499,510 Akoya BioSciences shares in Q3 2025, an estimated $649K.
- BlackRock first reported a position in Akoya BioSciences in Q2 2021 and held it in 17 quarters.
- BlackRock's Akoya BioSciences position peaked at $11.7M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.